A single T cell epitope drives the neutralizing anti-drug antibody response to natalizumab in multiple sclerosis patients

Natalizumab (NZM), a humanized monoclonal IgG4 antibody to α4 integrins, is used to treat patients with relapsing-remitting multiple sclerosis (MS)(1,2), but in about 6% of the cases persistent neutralizing anti-drug antibodies (ADAs) are induced leading to therapy discontinuation(3,4). To understan...

Descripción completa

Detalles Bibliográficos
Autores principales: Cassotta, Antonino, Mikol, Vincent, Bertrand, Thomas, Pouzieux, Stéphanie, Le Parc, Josiane, Ferrari, Paul, Dumas, Jacques, Auer, Michael, Deisenhammer, Florian, Gastaldi, Matteo, Franciotta, Diego, Silacci-Fregni, Chiara, Fernandez Rodriguez, Blanca, Giacchetto-Sasselli, Isabella, Foglierini, Mathilde, Jarrossay, David, Geiger, Roger, Sallusto, Federica, Lanzavecchia, Antonio, Piccoli, Luca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6795539/
https://www.ncbi.nlm.nih.gov/pubmed/31501610
http://dx.doi.org/10.1038/s41591-019-0568-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6795539/
https://www.ncbi.nlm.nih.gov/pubmed/31501610
http://dx.doi.org/10.1038/s41591-019-0568-2

Ejemplares similares